A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease

Recruiting

Phase 3

RilzabrutinibA 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease

Sponsor:

Sanofi

Code:

NCT07190196

Conditions

Immunoglobulin G4 Related Disease

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Rilzabrutinib

Placebo

Glucocorticoid

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-06-04. This information was provided to ClinicalTrials.gov by Sanofi on 2026-06-02.